The development of therapeutic CD8+ T-cell-based cancer vaccines and adoptive T-cell therapies is hindered by the lack of tumor-specific antigens (TSAs) that bind to MHC-I but do not evade T-cell self-tolerance. This evidence concerns the gene CD8A and cancer.